Medical Hospital
Resume:
RESUME
Michael John Leibold, PharmD, RPh
Curriculum Vitae: Summary
My professional career was initiated by the completion of two college B.S. degrees for a total of 240
credits, while receiving several academic awards including a BS magna cum laude (GPA 3.50) in Pre-
Med 1974, and a nomination for Outstanding Senior (senior class rank 3) while receiving a BS Pharm in
1977. I then proceeded into a career of hospital pharmacy practice by accruing experience at several
hospitals: St. Joseph’s Medical Center, Havasu Regional Hospital, Veteran’s Administration Hospital, and
Banner Boswell Medical Center. After almost two decades in hospital pharmacy practice, I enrolled in the
off campus post-graduate PharmD curriculum with the University of Arizona College of Pharmacy in
1993, and earned a PharmD degree summa cum laude (GPA 4.0) in 1998.
In addition to three college degrees in healthcare, I have maintained an extensive post-graduate
professional education in the form of more than 1500 hours of continuing education by 2013, and an
extensive familiarity with medical/ pharmaceutical literature via the maintenance of a large personal
professional library. This along with approximately 36 years of experience in hospital pharmacy practice
has allowed me to develop essential skills in the areas of pharmaceutical care, dispensing, compounding,
pharmacokinetics, and pharmacotherapeutics, which have contributed to my lifetime attempt to improve
patient care. These skills have been documented in a literary sense by the recent publication of an article
online at the Research Gate Website in September 2012 entitled “The Pitfalls of Dosing Warfarin with
Different Pharmacodynamic Models”, and the publication of a Letter to the Editor entitled “Optimal
Dabigatran Dosage In Patients with Moderate Renal Impairment” in the December 1, 2013 edition of the
American Journal of Health-System Pharmacists.
Publications URLs:
https://www.researchgate.net/profile/Michael_Leibold2/contributions/?ev=prf_act
http://www.ajhp.org/content/70/23/2067.full.pdf+html?
ct=33d378aa0048d58837b20bc26d4ee389e32cb57734bdd0715a84a59c16e65bf83716c13fd10041d075
ac320c5486a6e1b7647e5c8caf7c8d9462a709243ddd3f
http://www.beyond.com/my/portfolio/view/work-samples
Resume URLs:
http://www.linkedin.com/profile/view?id=205980720&trk=nav_responsive_tab_profile_pic
http://www.beyond.com/Michael-Leibold-AZ
Employment History
1
Banner Boswell Medical Center
March 1983 – Feb 2014(30 years 11 months) Sun City, Az
Staff Pharmacist
I processed inpatient medication orders in terms of computer order entry (CPOE) using the Cerner
system, and performed physical dispensing of medications including IV products. My dispensing
responsibilities included working with the Pyxis remote dispensing stations in terms of a physical
dispensing, and from a software perspective. I performed multiple clinical monitoring functions with an
emphasis on pharmacokinetic dosing of vancomycin and aminoglycosides, with some additional
monitoring of cardiovascular medications including antiarrhythmics and anticoagulants. I completed
many clinicaI consults and discerns with frequent communication with physicians and nurses staff. I
provided frequent drug information consults in response to the requests of physician and nursing staff.
Although I spent most of my career in the central pharmacy, I also obtained several years of experience
operating a satellite pharmacy on a CCU ward. During my career at Boswell Memorial Hospital, I
completed a post graduate PharmD between 1993-1998 with the University of Arizona off campus
program with a 4.0 GPA. I also published an article on Research Gate in 2012, and a Letter to the Editor
with AJHP in 2013. I earned an Employee of the Month Award for participating in a stroke alert in the
emergency room. I also earned a 30 Year Recognition of Service award for successful completion of 30
years of professional practice at Boswell Memorial Hospital in a contributory manner.
Veteran's Administration Hospital
May 1982 – December 1982 (8 months) Phoenix, Az
Staff Pharmacist
Professional experience gained here was in the form of inpatient drug dispensing, IV and TPN
compounding, transcription of patient drug profiles with the application of some pharmaceutical care
regarding patient drug therapy. I also gained some experience on the IOWA drug information microfiche
system.
Havasu Regional Hospital
July 1980 – May 1982 (1 year 11 months) Lake Havasu, Arizona
Chief Pharmacist
Professional experience at this position was in the form of implementation of various inpatient
pharmaceutical functions such as IV additive services including TPN compounding, unit dose distribution
services, as well as some clinical involvement such as participating in the pharmacy and therapeutics
committee and instituting some clinical pharmacokinetics services. I also gained some executive
experience in administrating the pharmacy department in terms of budgeting and managing materials and
personnel.
St. Joseph's Hospital and Medical Center
2
March 1978 – July 1980 (2 years 5 months) Phoenix, Arizona
Staff Pharmacist
Professional experience gained at this position was in the basic elements of inpatient hospital pharmacy
dispensing in the form of a centralized unit dose drug distribution system, and an IV additive
system(including TPN). The basic elements of monitoring inpatient drug therapy and the application of
pharmaceutical care were also acquired.
Honors & Awards
a) Employee of the Month
Banner Boswell Medical Center
March 2010
Awarded The Employee of the Month Award by Banner Boswell Medical Center for my successful
participation in a stroke alert in which the patient was treated with alteplase with a positive outcome.
ER physician nominated me for the award, which was later presented to me by the hospital administrator.
b) 30 Year Recognition of Service Award
Banner Boswell Medical Center
June 2013
Awarded the 30 Year Recognition of Service Award for successfully completing 30 years of professional
pharmacy practice in an contributory manner at Banner Boswell Medical Center.
c) Deans List Honors, BS Magna Cum Laude(Pre Med), PharmD Summa Cum Laude
University of Arizona
1970-1974, 1974-1978, 1993-1998
Deans List University of Arizona 1970-74 for GPA higher than 3.50. University Scholarship Honors
1970-75 for GPA >3.0. AED Pre Med Honorary Society. Alpha Tau Omega Vice President 1971-72,
Nominated Outstanding Senior by pharmacy class 1977 for class rank 3 based on GPA>3.0. Received BS
Pre-Med 1974 Magna Cum Laude for GPA 3.50. Received PharmD 1998 Summa Cum Laude for GPA
4.0.
Courses
1) Pharmacotherapy of Cardiovascular Disorders
3
American Society of Consultant Pharmacists 2013
Module 5 completed 7 CEU
2) Pharmacotherapy of Endocrine and Exocrine Disorders
American Society of Consultant Pharmacists 2013
Module 7 Completed 5 CEU
3) Applying Lab Values in Patient Care
University of Minnesota College of Pharmacy CE 2004
Completed 8 CEU
4) Concepts in Clinical Pharmacokinetics
American Society of Hospital Pharmacists 1988
Completed 20 CEU
5) Concepts in Oncology Therapeutics
American Society of Hospital Pharmacists 1991
Completed 20 CEU
6) Concepts in Immunology and Immunotherapeutics
American Society of Hospital Pharmacists 1990
Completed 22 CEU
7) Geriatric Pharmacy Review: Pharmacotherapy
American Society of Consultant Pharmacists
For Geriatric Pharmacy Certification: In Progress
8) 2012 Core Therapeutic Module, Cardiac Arrhythmias and ACLS
American Society of Health-System Pharmacists
Completed 1 CEU Feb 2014
9) 2013 National ACLS Testing Center
ACLS Certification Course: In Progress
10) 2013 National ACLS Testing center
4
BLS Certification Course: In Progress
Organizations
American Society of Health-System Pharmacists
Active Member
January 1983 – Present
American Pharmaceutical Association
Active Member
January 1990 – Present
Languages
English: Native proficiency
French: Elementary proficiency (college course)
Spanish: Elementary proficiency (high school course)
Publications
The Pitfalls of Warfarin Dosing Using Different Pharmacodynamic Models: A Comparison of Two
Different Warfarin Pharmacodynamic Models With Divergent Results
Publisher: Research Gate
September 1, 2012
URL: https://www.researchgate.net/profile/Michael_Leibold2/contributions/?ev=prf_act)
Abstract: Numerous articles have been published on warfarin pharmacogenetics in which the authors
provide regression equations for initial warfarin dose prediction based on patient pharmacogenetic
genotype. Hamberg et al(1) recently published the above inhibitory Emax-multicompartment transit
model for describing an observed delay of the effect of warfarin dosing on INR response, and proposed
that it may be used for a posteriori dosing based on dose/INR response.
Purpose: To investigate the possible application of the Hamberg et al(1) model to a posteriori dosing
based on dose/INR response.
Method: A comparison was made to a warfarin pharmacodynamic model commonly used for warfarin
dosing based on dose/INR response, the Modified Nagashima model.(2-9) Since the Hamberg et al(1)
model was formulated as a differential equation requiring numerical integration, an integrated version of
5
the Hamberg et al(1) pharmacodynamic model was derived which created a spreadsheet version which
could be compared to a spreadsheet version of the Modified Nagashima model. (2-8)
Results: The Hamberg(1) model severely diverged from the Modified Nagashima model with respect to
dose-INR response.
Conclusion: Based on these results and expert pharmacodynamic literature, the Hamberg et al(1)
pharmacodynamic model is applicable as an “empirical mathematical function to describe the shape of
the concentration-effect relationship” of the delayed effect of warfarin on INR response, and not
necessarily a dosing tool. The pharmacist should consider warfarin pharmacogenetic literature as a guide
to initial warfarin dosing, and not as a tool to determine subsequent warfarin doses based on clinical
observations of warfarin dose-INR response.
Optimal Dabigatran Dosage In Patients with Moderate Renal Impairment
Publisher: American Journal of Health-System Pharmacists
December 1, 2013, Volume 70, Number 23, p 2067-68
URL: http://www.ajhp.org/content/70/23/2067.full.pdf+html?
ct=33d378aa0048d58837b20bc26d4ee389e32cb57734bdd0715a84a59c16e65bf83716c13fd10041d075
ac320c5486a6e1b7647e5c8caf7c8d9462a709243ddd3f
In the May 2013 AJHP supplement, Nutescu cited an alarming number of serious adverse bleeding
reactions to dabigatran compared to warfarin as reported to the MedWatch program 2011. Nutescu also
stated that most complications from dabigatran reported to FDA occurred in elderly patients, many of
whom had impaired renal function. Several publications have shown that dabigatran concentration may
be three times higher in patients with moderate renal impairment (creatinine clearance [CLcr], 30–50
mL/min) than in patients with better renal function (CLcr, >50 mL/min). In order to determine an
appropriate dosage reduction for patients with moderate renal impairment, data from Table 1 in Nutescu’s
article associating CLcr with dabigatran’s half-life were used to derive a linear regression equation
relating CLcr to dabigatran’s elimination rate constant k (i.e., k = 0.0041CLcr + 0.0163). This information
was also used to calculate the steady-state dabigatran concentration (Css) that would result from various
dabigatran dosage regimens for patients with varying degrees of renal function. The concentrations were
calculated from the equation Css = FD/ τCL, where F (bioavailability) = 0.05, D = dose, τ = dosing
interval, and CL (dabigatran clearance) = kV, where V (volume of distribution) = 60 L. These
calculations provided the basis for an optimized dosing scheme involving a 110mg BID dose in the 30-
50ml/min creatinine clearance group which would minimize bleeding risk while maintaining therapeutic
efficacy. Although the equations differed, the calculations presented in this article agree in terms of the
estimated Css values with several other publications on dabigatran pharmacokinetics, including an article
published by the manufacturers of dabigatran.
Projects
6
Warfarin pharmacodynamics: reconciliation of pharmacogenetic and pharmacodynamic
modeling
Pharmacogeneticists, while possessing unique and valuable data on the genetic basis of warfarin
response and dosing, have so far only been able to couple this information with only one warfarin
pharmacodynamic model- the inhibitory Emax model. The inhibitory Emax model only describes the
temporal shape of a pharmacodynamic response curve, and does not incorporate the
pharmacological/physiological causation involved. The Modified Nagashima Model incorporates
pharmacological and physiological causation while providing an accurate temporal based
pharmacodynamic response curve, similar in shape to the inhibitory Emax model. Integrating the
pharmacogentic information provided by the geneticists into the Modified Nagashmia pharmacodynamic
model would reconcile the pharmacogenetic information with an accurate pharmacodynamic model based
on real pharmacological/ physiological causation.
Optimal Dabigatran Dosage In Patients with Moderate Renal Impairment
In the May 2013 AJHP supplement, Nutescu cited an alarming number of serious adverse bleeding
reactions to dabigatran compared to warfarin as reported to the MedWatch program 2011. Nutescu also
stated that most complications from dabigatran reported to FDA occurred in elderly patients, many of
whom had impaired renal function. As described in publications, some information provided in the
Nutesco article regarding CrCl and dabigatran half-life was used to determine an appropriate regression
equation that would allow the calculation of the steady-state dabigatran concentration (Css) that would
result from various dabigatran dosage regimens for patients with varying degrees of renal function. These
calculations provided the basis for an optimized dosing scheme involving a 110mg BID dose in the 30-
50ml/min creatinine clearance group which would minimize bleeding risk while maintaining therapeutic
efficacy. Although the equations differed, the calculations presented in this article agree in terms of the
estimated Css values with several other publications on dabigatran pharmacokinetics, including an article
published by the manufacturers of dabigatran. I am continuing to review the literature regarding
dabigatran pharmacokinetics and intend to compare the various calculations that have been published, and
whether they would support a 110mg BID dose for the 30-50ml/min creatinine clearance group.
Education
University of Arizona
Doctor of Pharmacy (PharmD), 4.0 GPA
1993 – 1998
Activities and Honors: Completed research paper on Once Daily Aminoglycoside Dosing. I also authored
several spreadsheets for pharmacokinetic dosing involving Bayesian Regression.
University of Arizona
BS Pharm, Senior Class Rank 3
Activities and Honors: Nominated for Outstanding Senior 1977, University Scholarship Honors 1974
7
1974-1977
University of Arizona
BS Pre Med GPA 3.50
1970 – 1974
Activities and Honors: Vice President Alpha Tau Omega Fraternity, AED Pre-Med Honorary Society,
University Scholarship Honors 1970-1974, Deans List 1971-1974
Interests
I am pursuing interests in pharmacodynamics, pharmacokinetics and Bayesian regression. I have
published two papers on anticoagulant pharmacodynamics and pharmacokinetics: warfarin and
dabigatran. Pursuing these same interests, I have also authored several pharmacokinetic spreadsheets for
dosing vancomycin, aminoglycosides, phenytoin and warfarin. As detailed earlier in the resume, I am
working on two projects involving warfarin pharmacodynamics/ pharmacogenetics and dabigatran
dosing.
8
Contact this candidate